Welcome to the DDRiver™ Clinical Trials Program

If you are an HCP, click on “I’m a Healthcare Professional"

If you are a patient, please click on “I’m not a Healthcare Professional”

Leaving DDRiver™ website

You are leaving DDRiver™ Clinical Trials page. This link will take you to a website where our Terms of Use do not apply. EMD Serono does not control the content of these websites.

mask group1 Not an actual patient

DDRiverTM Clinical Trials Program

The drugs in the DDRiverTM clinical trials program are under clinical investigation and have not yet been proven to be safe and effective. There is no guarantee that any therapies in the clinical trials program will be approved in the sought-after indication by any health authority worldwide.

The DDRiverTM website only highlights DDR inhibitor studies that are sponsored by EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada.

group 145 Not an actual patient

Programs

Logo1

Tuvusertib in Solid Tumors

A phase 1, open-label trial evaluating tuvusertib in patients with metastatic or locally advanced unresectable solid tumors

Tuvusertib is an investigational orally administered inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase1-3

logo 2

Tuvusertib in Solid Tumors

A phase 1, open-label trial evaluating tuvusertib in patients with metastatic or locally advanced unresectable solid tumors

Tuvusertib is an investigational orally administered inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase1-3

logo 2

Tuvusertib in Solid Tumors

A phase 1B, open-label trial evaluating tuvusertib in combination with DNA damage response inhibitors or immune checkpoint inhibitors in patients with metastatic or locally advanced unresectable solid tumors

Tuvusertib is an investigational orally administered inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase1, 4, 5

Logo1

Tuvusertib in Solid Tumors

A phase 1B, open-label trial evaluating tuvusertib in combination with DNA damage response inhibitors or immune checkpoint inhibitors in patients with metastatic or locally advanced unresectable solid tumors

Tuvusertib is an investigational orally administered inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase1, 4, 5

logo 2

Tuvusertib in NSCLC

A phase 1B/2A, open-label trial evaluating tuvusertib in combination with cemiplimab in patients with non-squamous non-small cell lung cancer that has progressed on prior anti–PD-(L)1 and platinum-based therapies

Tuvusertib is an investigational orally administered inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase1, 6

Logo1

Tuvusertib in NSCLC

A phase 1B/2A, open-label trial evaluating tuvusertib in combination with cemiplimab in patients with non-squamous non-small cell lung cancer that has progressed on prior anti–PD-(L)1 and platinum-based therapies

Tuvusertib is an investigational orally administered inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase1,6

logo

Lartesertib in Solid Tumors  

A phase 1, open-label trial evaluating lartesertib in patients with advanced solid tumors

Lartesertib is an investigational orally administered ATP-competitive inhibitor of ataxia telangiectasia mutated (ATM) protein kinase7, 8

Visit clinicaltrials.gov to learn about more our DDR inhibitor studies conducted in collaboration with external partners.

References

1. Roidos P, et al. Nat Commun. 2020;11(1):4077; 2. Yap TA, et al. Clin Cancer Res. Published online February 26, 2024, doi:10.1158/1078-0432.CCR-23-2409; 3. ClinicalTrials.gov. Accessed March 29, 2024. https://clinicaltrials.gov/ct2/show/NCT04170153; 4. Siu L, et al. Cancer Res. 2024;84 (Supp 7): CT063;
5. ClinicalTrials.gov. Accessed March 29, 2024. https://clinicaltrials.gov/ct2/show/NCT05396833; 6. ClinicalTrials.gov. Accessed March 29, 2024.
https://clinicaltrials.gov/study/NCT05882734; 7. Zimmermann A, et al. Mol Cancer Ther. 2022;21(6):859-870; 8. ClinicalTrials.gov. Accessed March 29, 2024. https://clinicaltrials.gov/ct2/show/NCT04882917.